logo-loader
RNS
viewArix Bioscience PLC

Arix Bioscience Plc - Management change

Arix Bioscience plc

Management change

(“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the departure of Chief Financial Officer, and promotion of Group Financial Controller, to Group Finance Director. These changes take place with immediate effect., :LONDON2 October 2019Arix Bioscience plcJames RawlingsonMarcus Karia

, Chief Executive Officer commented:Joe Anderson

“On behalf of the board I’d like to thank James for his contribution to Arix in the first stage of our development and wish him well in his future endeavours.”

Enquiries:

For more information on Arix, please contact:

Arix Bioscience plc

, Head of Investor RelationsCharlotte Parry

+44 (0)20 7290 1072

 [email protected]

Optimum Strategic Communications

Mary Clark,Supriya Mathur

+44 (0)203 950 9144

[email protected]

AboutArix Bioscience plc

is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.Arix Bioscience plc

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

www.arixbioscience.com

Quick facts: Arix Bioscience PLC

Price: 86.5

Market: LSE
Market Cap: £117.3 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018